Silence Therapeutics (SLN) Gross Margin (2024 - 2026)

Silence Therapeutics has disclosed Gross Margin across 3 years of filings, most recently posting 97.39% for Q1 2026.

• Gross Margin for Q1 2026 came in at 97.39%, up 3542.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.84% (up 1456.0% YoY), and the FY2025 annual result was 61.54%, down 1116.0% from the prior year.
• Gross Margin came in at 97.39% for Q1 2026 at Silence Therapeutics, up from 64.71% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 97.39% in Q1 2026 to a low of 340.87% in Q2 2024.
• The 3-year median for Gross Margin is 64.71% (2025), against an average of 4.85%.
• Peak annual rise in Gross Margin reached 41037 bps in 2025, while the deepest fall reached 2724 bps in 2025.
• Silence Therapeutics' Gross Margin stood at 91.95% in 2024, then fell by 30 bps to 64.71% in 2025, then jumped by 51 bps to 97.39% in 2026.
• The last three Gross Margin figures came in at 97.39% (Q1 2026), 64.71% (Q4 2025), and 59.75% (Q3 2025), per Business Quant data.